ORCID as entered in ROS

Select Publications
2024, TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125383.v1
,2024, TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study, http://dx.doi.org/10.1158/2767-9764.26125383
,2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.c.6762576.v2
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.24071513
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.24071513.v1
,2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.c.6762576.v1
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.23791947
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, http://dx.doi.org/10.1158/1078-0432.23791947.v1
,